Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epicutaneous Immunotherapy in Peanut Allergy in Children
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
This study aims at showing that Epicutaneous Immunotherapy with peanut proteins is safe and efficacious for desensitizing children with peanut allergy.
Official title: ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut
Key Details
Gender
All
Age Range
5 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2010-08
Completion Date
2015-04
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
Epicutaneous Immunotherapy
100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
placebo of peanut
placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
Locations (1)
Hopital Necker
Paris, France